KRAS and lung carcinoma: Additionally, the development of targeted therapies such as gefitinib for EGFR, salirasib for KRAS, and O6-benzylguanine for MGMT has failed to confer significant therapeutic benefits for lung cancer and GBM patients13,15,20, likely due to their inconsistent prognostic and predictive value23.